Eupraxia Pharmaceuticals Inc.: Form 40-F for the period ended Dec 31, 2024
Filed with the SEC on Mar 20, 2025 and accepted by EDGAR at Mar 20, 2025, 20:55 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2024-01-01 to 2024-12-31 | $0 | us-gaap:Revenues |
| Research and development | 12 months2024-01-01 to 2024-12-31 | $16.1m | us-gaap:ResearchAndDevelopmentExpense |
| Interest expense | 12 months2024-01-01 to 2024-12-31 | $603.6k | us-gaap:InterestExpense |
| Income tax | 12 months2024-01-01 to 2024-12-31 | $1.8k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2024-01-01 to 2024-12-31 | −$25.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | −$0.76 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | −$0.76 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2024-01-01 to 2024-12-31 | 33,930,575 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −$30.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-12-31 | $33.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $34.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $34.9m | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $3.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $3.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-12-31 | $33.4m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2024-12-31 | 35,641,603 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001193125-25-059352. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.